title: Postoperative radiotherapy for locally advanced colon cancer.
abstract: BACKGROUND
  The role of adjuvant postoperative radiotherapy for locally advanced colon cancer is not well documented.
  
  
  METHODS
  Seventy-eight patients who underwent a complete resection of B2-C colon cancer received postoperative radiotherapy. Twenty-eight patients received < or = 45 Gy; 50 patients received 50-55 Gy. Twenty-seven patients received adjuvant fluorouracil-based chemotherapy. All patients were followed for a minimum of 3 years; no patients were lost to follow-up.
  
  
  RESULTS
  The overall local control rate was 88%. The 5-year actuarial rate of local control was 96% after 50-55 Gy postoperative radiotherapy compared with 76% after < 50 Gy (p = 0.0095). Multivariate analysis of local control showed that only radiotherapy dose significantly influenced this end point. Cause-specific survival rates at 5 years were B2, 67%; B3, 90%; C1, 100%; C2, 61%; C3, 36%; and overall, 63%. Multivariate analysis of cause-specific survival showed that only stage significantly influenced this end point. Bowel obstruction caused by adhesions developed in three patients and required a laparotomy; radiation-induced sarcoma developed in one additional patient.
  
  
  CONCLUSIONS
  Postoperative radiotherapy appears to reduce the risk of local recurrence in patients with locally advanced colon cancer. The optimal dose is probably 50-55 Gy at 1.8 Gy per fraction. Postoperative radiotherapy may improve cause-specific survival for patients with stages B3 and C2 cancers.
authors.affiliation: Department of Radiation Oncology, West Florida Cancer Institute, Pensacola 32514-6050, USA.
authors.forename: E H
authors.initials: EH
authors.lastname: Amos
authors.forename: W M
authors.initials: WM
authors.lastname: Mendenhall
authors.forename: P J
authors.initials: PJ
authors.lastname: McCarty
authors.forename: J O
authors.initials: JO
authors.lastname: Gage
authors.forename: J L
authors.initials: JL
authors.lastname: Emlet
authors.forename: G C
authors.initials: GC
authors.lastname: Lowrey
authors.forename: C A
authors.initials: CA
authors.lastname: Peterson
authors.forename: W R
authors.initials: WR
authors.lastname: Amos
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011182:Postoperative Care; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil